share_log

Here's Why We Think CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Looks Fair for the Time Being

Here's Why We Think CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Looks Fair for the Time Being

这是我们认为CorMedix Inc.(纳斯达克:CRMD)首席执行官的薪酬在目前看起来合理的原因。
Simply Wall St ·  11/14 06:53

Key Insights

关键见解

  • CorMedix to hold its Annual General Meeting on 21st of November
  • Total pay for CEO Joe Todisco includes US$617.0k salary
  • The overall pay is comparable to the industry average
  • CorMedix's total shareholder return over the past three years was 124% while its EPS was down 7.3% over the past three years
  • Cormedix 将于 11 月 21 日举行年度股东大会
  • 首席执行官乔·托迪斯科的总薪水包括617.0万美元的工资
  • 总体薪酬与行业平均水平相当
  • 在过去三年中,CormediX的股东总回报率为124%,而其每股收益在过去三年中下降了7.3%

Performance at CorMedix Inc. (NASDAQ:CRMD) has been reasonably good and CEO Joe Todisco has done a decent job of steering the company in the right direction. As shareholders go into the upcoming AGM on 21st of November, CEO compensation will probably not be their focus, but rather the steps management will take to continue the growth momentum. Based on our analysis of the data below, we think CEO compensation seems reasonable for now.

CorMedix Inc.(纳斯达克股票代码:CRMD)的表现相当不错,首席执行官乔·托迪斯科在引导公司朝着正确的方向前进方面做得不错。随着股东进入即将于11月21日举行的股东大会,首席执行官薪酬可能不是他们的重点,而是管理层为延续增长势头将采取的措施。根据我们对以下数据的分析,我们认为首席执行官的薪酬目前似乎是合理的。

How Does Total Compensation For Joe Todisco Compare With Other Companies In The Industry?

与业内其他公司相比,乔·托迪斯科的总薪酬如何?

According to our data, CorMedix Inc. has a market capitalization of US$708m, and paid its CEO total annual compensation worth US$2.5m over the year to December 2023. That's a notable decrease of 15% on last year. We think total compensation is more important but our data shows that the CEO salary is lower, at US$617k.

根据我们的数据,Cormedix Inc.的市值为7.08亿美元,在截至2023年12月的一年中,向其首席执行官支付的年薪总额为250万美元。这比去年显著下降了15%。我们认为总薪酬更为重要,但我们的数据显示,首席执行官的薪水较低,为61.7万美元。

For comparison, other companies in the American Pharmaceuticals industry with market capitalizations ranging between US$400m and US$1.6b had a median total CEO compensation of US$2.9m. This suggests that CorMedix remunerates its CEO largely in line with the industry average. Moreover, Joe Todisco also holds US$2.1m worth of CorMedix stock directly under their own name, which reveals to us that they have a significant personal stake in the company.

相比之下,美国制药行业中市值在4亿美元至16亿美元之间的其他公司的首席执行官总薪酬中位数为290万美元。这表明CorMedix的首席执行官薪酬基本符合行业平均水平。此外,乔·托迪斯科还直接以自己的名义持有价值210万美元的CorMedix股票,这向我们表明他们在该公司拥有大量个人股份。

Component 2023 2022 Proportion (2023)
Salary US$617k US$378k 25%
Other US$1.8m US$2.5m 75%
Total Compensation US$2.5m US$2.9m 100%
组件 2023 2022 比例 (2023)
工资 617k 美元 378 万美元 25%
其他 180 万美元 2.5 万美元 75%
总薪酬 2.5 万美元 290 万美元 100%

On an industry level, around 28% of total compensation represents salary and 72% is other remuneration. CorMedix is largely mirroring the industry average when it comes to the share a salary enjoys in overall compensation. If non-salary compensation dominates total pay, it's an indicator that the executive's salary is tied to company performance.

在行业层面,总薪酬中约有28%代表工资,72%是其他薪酬。就工资在总薪酬中所占份额而言,CormediX在很大程度上反映了行业平均水平。如果非工资薪酬在总薪酬中占主导地位,则表明高管的薪水与公司业绩息息相关。

big
NasdaqGM:CRMD CEO Compensation November 14th 2024
纳斯达克通用汽车公司:CRMD 首席执行官薪酬 2024 年 11 月 14 日

A Look at CorMedix Inc.'s Growth Numbers

看看 Cormedix Inc.”s 增长数字

Over the last three years, CorMedix Inc. has shrunk its earnings per share by 7.3% per year. Its revenue is up 41,184% over the last year.

在过去的三年中,CorMedix Inc.的每股收益每年缩水7.3%。其收入比去年增长了41,184%。

Investors would be a bit wary of companies that have lower EPS But on the other hand, revenue growth is strong, suggesting a brighter future. It's hard to reach a conclusion about business performance right now. This may be one to watch. Moving away from current form for a second, it could be important to check this free visual depiction of what analysts expect for the future.

投资者会对每股收益较低的公司保持警惕,但另一方面,收入增长强劲,这表明前景更加光明。目前很难就业务绩效得出结论。这可能值得关注。暂时偏离目前的形式,查看这份对分析师未来预期的免费可视化描述可能很重要。

Has CorMedix Inc. Been A Good Investment?

CorMedix Inc. 是一项不错的投资吗?

We think that the total shareholder return of 124%, over three years, would leave most CorMedix Inc. shareholders smiling. As a result, some may believe the CEO should be paid more than is normal for companies of similar size.

我们认为,三年内124%的股东总回报率将使大多数Cormedix Inc.股东微笑。因此,有些人可能认为,首席执行官的薪水应该高于类似规模公司的正常水平。

In Summary...

总而言之...

Some shareholders will be pleased by the relatively good results, however, the results could still be improved. Despite robust revenue growth, until EPS growth improves, shareholders may be hesitant to increase CEO pay by too much.

一些股东会对相对不错的业绩感到高兴,但是,业绩仍有改善的余地。尽管收入增长强劲,但在每股收益增长改善之前,股东们可能会对过多地增加首席执行官薪酬犹豫不决。

While CEO pay is an important factor to be aware of, there are other areas that investors should be mindful of as well. We did our research and spotted 3 warning signs for CorMedix that investors should look into moving forward.

尽管首席执行官的薪酬是一个需要注意的重要因素,但投资者还应注意其他领域。我们进行了研究,发现了CormediX的3个警告信号,投资者应考虑向前迈进。

Switching gears from CorMedix, if you're hunting for a pristine balance sheet and premium returns, this free list of high return, low debt companies is a great place to look.

如果你正在寻找良好的资产负债表和保费回报,那么这份免费的高回报、低负债公司的清单是一个不错的选择。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?担心内容吗?直接联系我们。或者,发送电子邮件给编辑组(网址为)simplywallst.com。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发